Aratana Therapeutics Inc (NASDAQ:PETX) has been assigned a consensus rating of “Hold” from the nine research firms that are presently covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $8.75.
Several research analysts have recently issued reports on the company. Stifel Nicolaus reissued a “hold” rating and issued a $6.00 price target on shares of Aratana Therapeutics in a research note on Monday, December 18th. HC Wainwright set a $10.00 price objective on Aratana Therapeutics and gave the company a “buy” rating in a report on Thursday, December 21st. Zacks Investment Research lowered Aratana Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, November 18th. Jefferies Group restated a “buy” rating and issued a $8.00 price objective on shares of Aratana Therapeutics in a report on Friday, November 3rd. Finally, ValuEngine lowered Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st.
In other news, insider Peter Steven St sold 50,000 shares of the company’s stock in a transaction on Friday, November 10th. The stock was sold at an average price of $7.00, for a total value of $350,000.00. Following the completion of the sale, the insider now owns 529,359 shares in the company, valued at $3,705,513. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Craig A. Tooman sold 30,000 shares of the company’s stock in a transaction on Thursday, January 11th. The shares were sold at an average price of $5.27, for a total value of $158,100.00. Following the sale, the insider now directly owns 75,024 shares of the company’s stock, valued at $395,376.48. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,087,032 shares of company stock valued at $6,344,891. Insiders own 5.20% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Janus Henderson Group PLC lifted its holdings in shares of Aratana Therapeutics by 0.6% during the third quarter. Janus Henderson Group PLC now owns 1,801,381 shares of the biopharmaceutical company’s stock valued at $11,042,000 after purchasing an additional 10,551 shares during the last quarter. Alyeska Investment Group L.P. lifted its holdings in shares of Aratana Therapeutics by 10.5% during the third quarter. Alyeska Investment Group L.P. now owns 964,116 shares of the biopharmaceutical company’s stock valued at $5,910,000 after purchasing an additional 91,763 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Aratana Therapeutics by 2.0% during the third quarter. Dimensional Fund Advisors LP now owns 388,437 shares of the biopharmaceutical company’s stock valued at $2,381,000 after purchasing an additional 7,542 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Aratana Therapeutics by 20.8% during the third quarter. Wells Fargo & Company MN now owns 367,365 shares of the biopharmaceutical company’s stock valued at $2,252,000 after purchasing an additional 63,377 shares during the last quarter. Finally, Cadence Capital Management LLC lifted its holdings in shares of Aratana Therapeutics by 5.1% during the third quarter. Cadence Capital Management LLC now owns 173,808 shares of the biopharmaceutical company’s stock valued at $1,065,000 after purchasing an additional 8,449 shares during the last quarter. 73.74% of the stock is owned by institutional investors and hedge funds.
Aratana Therapeutics (NASDAQ PETX) traded down $0.08 during trading hours on Tuesday, hitting $4.82. The stock had a trading volume of 118,452 shares, compared to its average volume of 582,840. Aratana Therapeutics has a 12 month low of $4.63 and a 12 month high of $8.08. The company has a market capitalization of $205.68, a PE ratio of -3.33 and a beta of 3.36. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.08 and a current ratio of 3.42.
Aratana Therapeutics (NASDAQ:PETX) last released its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.24) by $0.03. Aratana Therapeutics had a negative return on equity of 48.79% and a negative net margin of 358.55%. The company had revenue of $6.16 million during the quarter, compared to analysts’ expectations of $6.47 million. During the same quarter in the prior year, the business posted ($0.38) earnings per share. The company’s revenue for the quarter was up 1440.0% compared to the same quarter last year. equities analysts expect that Aratana Therapeutics will post -1.03 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Aratana Therapeutics Inc (PETX) Receives Consensus Rating of “Hold” from Brokerages” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/30/aratana-therapeutics-inc-petx-receives-consensus-rating-of-hold-from-brokerages.html.
Aratana Therapeutics Company Profile
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.